CME: Who ‘nose’ the best path forward? Improving awareness and optimizing the management of recurrent or metastatic nasopharyngeal carcinoma
Activity Description / Statement of Need:
In this online, self-learning activity:
Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States with an age-standardized incidence rate of 0.41 per 100,000 population, NPC is endemic to certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus positivity.
Target Audience:
HCPs including but not limited to: medical oncologists, radiation oncologists, and otolaryngologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and any other clinicians who are involved or interested in the treatment of recurrent or metastatic NPC.
Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences.
This activity is free of charge.
Release Date: July 30, 2025 -- Expiration Date: July 30, 2026
Faculty: Michael Dennis, MD
Agenda
|
Faculty introduction and disclosures |
|
NPC identification and burden ● Epidemiology and global distribution of NPC ● Risk factors for NPC, recurrence, and distant metastases ● Burden of disease |
|
Integrating novel and emerging treatments for recurrent or metastatic NPC ● First-line therapy ○ Combination chemotherapy: gemcitabine/cisplatin vs other options ○ Consideration of the addition of immunotherapy ● Later-line therapy decision-making ○ Immunotherapy vs. chemotherapy ○ Role of biomarkers ○ Choice of immunotherapy ● Investigational agents ○ Novel agents ○ Novel combinations ○ Encouraging consideration of clinical trial enrollment ● Importance of the MDT ○ Strategies for multidisciplinary care ○ Selecting and sequencing localized and systemic therapy ○ Recognition, management, and mitigation of treatment-related adverse events, including in patients receiving immunotherapy ○ Related patient education and patient-reported outcomes ● Putting it all together: patient case(s) |
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Review risk factors for the development and progression of NPC, including the identification of patients at high risk for distant metastases.
- Compare systemic treatment regimens available for the management of recurrent or metastatic NPC.
- Evaluate the evidence supporting the safety and efficacy of various treatment approaches for recurrent or metastatic NPC.
- Individualize treatment for a patient with metastatic NPC using guideline recommendations and multidisciplinary strategies.
Accreditation
ACCME Activity #203279196
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-25-014-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™, and the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ to meet the continuing education renewal requirements of nursing re-certification for APRNs and RN specialty. Some state nursing boards accept AMA PRA Category 1 Credit(s)™ for re-licensure requirements, some do not. Check your state board of nursing's CE requirements before applying credit from this course to your re-licensure.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Michael Dennis, MD, Medical Oncologist, Division of Head and Neck Oncology, Harvard Medical School, has received financial compensation from Coherus BioSciences and Corbus Pharmaceuticals as a consultant; in addition to speaker’s bureau work for Dr. Reddy’s Laboratories.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
A clear-eyed view of the path forward advanced renal cell carcinoma (RCC) treatment
Turning the tide toward precision care for metastatic urothelial carcinoma
Pancreatic Cancer: Updates from the European Society of Medical Oncology (ESMO) Annual Meeting